Medidata Solutions (NASDAQ:MDSO)

CAPS Rating: 2 out of 5

Results 1 - 7 of 7

Recs

0
Member Avatar TSIF (99.96) Submitted: 2/8/2016 3:38:03 PM : Outperform Start Price: $34.47 MDSO Score: -4.24

I've been watching this one a long time..back when it looked like a possible growth stock...looks like the price PLUGED into my low, let's tag it, watch it, but not call it for awhile limit range...

Overall, I still think this one has some good potential. Unfortunately it's still forward priced, which puts it on the possible dump with the baby in the bath water group. Also, I don't really like that the only attention it is getting is from the pumper style financial rags and it's own PR firm touting wins that should be everyday business...(seems everyday)...and not news...

So while P/B and P/S are still a little high in this environment, institutional holding is high, and I like this entry. Product portfolio and customer base, although customer arenas are especially challenged, looks promising.

Target...watching...

Recs

0
Member Avatar murphydevani (66.39) Submitted: 8/28/2015 9:07:07 AM : Underperform Start Price: $47.41 MDSO Score: +22.71

Target $45 - $41

Recs

0
Member Avatar TMFTypeoh (73.15) Submitted: 10/24/2013 3:58:00 PM : Outperform Start Price: $61.08 MDSO Score: -50.52

Riding to cloud wave

Recs

0
Member Avatar DanaFBlankenhorn (< 20) Submitted: 2/28/2013 1:24:29 PM : Outperform Start Price: $25.98 MDSO Score: +6.92

They have succeeded in taking control of the clinical trials market, but this market is not subject to the stimulus the way the EHR market is.

Recs

0
Member Avatar rjs157 (57.80) Submitted: 10/10/2012 9:56:29 PM : Outperform Start Price: $19.94 MDSO Score: +38.26

SaaS cloud storage of medical records...genius

Recs

0
Member Avatar jalibistje (< 20) Submitted: 12/25/2009 2:16:53 PM : Outperform Start Price: $7.70 MDSO Score: +265.44

I think that Elan's Tysabri is becomming the best for all MS patients and only for this the stock can outperform the market. Elan also has several issues for the disease of Alsheimer and that can take the stock going like GILD did the past ten year.

Recs

0
Member Avatar kong777 (64.55) Submitted: 9/29/2009 2:01:42 PM : Outperform Start Price: $7.74 MDSO Score: +252.90

The bottom for this company is thin . But the beauty inside is impressive . Robust revenue growth year by year . The cash flow is strong. Net income might be low but it is norm when your company is in growing mode. A lot of depreciation makes the bottom line look bad but CF is far more better.

The revenue stream is recurring because it is in service business. 80% of customer retention . And the Biotech sector is blooming like Obama said and the aging economy . Everything looks great for this small company. So I would say "long term buy"

Results 1 - 7 of 7

Featured Broker Partners